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Chloroquine could be used for the treatment of ﬁloviral infections and
other viral infections that emerge or emerged from viruses requiring an
acidic pH for infectivity
Hephzibah Akpovwa*
Cardiff School of Biosciences, Cardiff University, Cardiff, UK
Viruses from the Filoviridae family, as many other virus families, require an acidic pH for successful infection and are therefore susceptible to
the actions of 4-aminoquinolines, such as chloroquine.
Although the mechanisms of action of chloroquine clearly indicate that it might inhibit ﬁloviral infections, several clinical trials that
attempted to use chloroquine in the treatment of other acute viral infections – including dengue and inﬂuenza A and B – caused by low
pH-dependent viruses, have reported that chloroquine had no clinical efﬁcacy, and these results demoted chloroquine from the potential treatments
for other virus families requiring low pH for infectivity.
The present review is aimed at investigating whether chloroquine could combat the present Ebola virus epidemic, and also at exploring the
main reasons for the reported lack of efﬁcacy. Literature was sourced from PubMed, Scopus, Google Scholar, reference list of articles and
textbooks – Fields Virology (Volumes 1and 2), the cytokine handbook, Pharmacology in Medicine: Principles and Practice, and
hydroxychloroquine and chloroquine retinopathy.
The present analysis concludes that (1) chloroquine might ﬁnd a place in the treatment of Ebola, either as a monotherapy or in combination
therapies; (2) the ineffectiveness of chloroquine, or its analogue, hydroxychloroquine, at treating infections from low pH-dependent viruses is
a result of the failure to attain and sustain a steady state concentration sufﬁcient to increase and keep the pH of the acidic organelles to
approximately neutral levels; (3) to successfully treat ﬁloviral infections – or other viral infections that emerge or emerged from low
pH-dependent viruses – a steady state chloroquine plasma concentration of at least 1 μg/mL(~3.125 μM/L) or a whole blood concentration
of 16 μM/L must be achieved and be sustained until the patients’ viraemia becomes undetectable. These concentrations, however, do not
rule out the efﬁcacy of other, higher, steady state concentrations – although such concentrations might be accompanied by severe adverse
effects or toxicities. The feasibility of the conclusion in the preceding texts has recently been supported by a subsequent study that shows that
amodiaquine, a derivative of CQ, is able to protect humans infected with Ebola from death. Copyright © 2016 John Wiley & Sons, Ltd.
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INTRODUCTION
The Filoviridae family – containing Ebola andMarburg viruses
– comprises enveloped viruses with nonsegmented, negative-
sense RNA genomes,1–3 each of which consists of seven genes
forming the structural and nonstructural proteins.1,2 Of all
ﬁloviruses, the currently circulating Zaire species of Ebola virus
(EboV) is the most virulent, with a mortality rate ranging from
59 to 88%.1,2
The peplomers of the EboV species are composed of
trimerized heterodimers of glycoproteins 1 and 2, which
are heavily glycosylated with both N-linked and O-linked
glycans, and contain abundant α(2-6) and/or α(2-3) linked
sialic acids.1–3 These peplomers have broad tropism for a
variety of host cells and organs as a result of their ability
to bind either speciﬁcally or nonspeciﬁcally to various cell
surface molecules.1,2,4–8 However, despite this broad tropism,
infection by ﬁloviruses greatly depends on the acidic pH of the
organelles internalizing the virus,1,2,8–10 and therefore this
characteristic can be exploited therapeutically.
Filovirus binding to surface molecules on the plasma
membrane of susceptible cells – such as tissue macrophages,
monocytes, dendritic cells, endothelial cells and hepatocytes –
leads to the internalization of virions into vesicles which trafﬁc
through the endosomal pathway.1,2,8–10 To successfully infect
susceptible cells, the virus requires endosomal acidiﬁcation
and the cleavage of the glycoprotein 1 segment of the
peplomer by host endosomal proteases (active in acidic
pH)1,2,8–10 and, without this acidiﬁcation and cleavage, the in-
fection is abrogated.1,2,10 Therefore, therapeutic agents
targeting endosomal acidiﬁcation (and hence pH-dependent
proteases), could be beneﬁcial in combating the present
African EboV epidemic.
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Successful infection induces the local and systemic re-
lease of varying amounts of cytokines, chemokines, reactive
oxygen species, nitric oxide and other mediators,1,2,11–14
and eventually results in generalized cell death.1,2,11–13 If a
patient’s immune system is able to control the infection,
the patient recovers1,2,11–14 – although convalescence is
prolonged, and recovering patients have been shown to
produce infectious virus many months after symptoms
have disappeared.1,2 However, if a patient’s immune system
is unable to control the infection, further cycles of infection
in susceptible cells and organs occur, leading to further release
of the mediators mentioned in the preceding texts, with conse-
quently massive cell death.1,2,11–13 This is manifested in fatal
cases as extensive cell death in many organs – including the
liver, spleen, lymph nodes, kidney and adrenal glands –
and coagulopathies, which are revealed as disseminated intra-
vascular coagulation, haemorrhages, petechiae, ecchymosis,
congestion and uncontrolled bleeding at venipuncture
sites.1,2,11–13 The mode of infection of ﬁloviruses and the
associated pathologies may uncover an Achilles’ heel to a
therapeutic weaponry based on 4-aminoquinolines such
as chloroquine (CQ).
Therapeutically exploiting the tropism of chloroquine for
the acidic organelles in the treatment of ﬁloviral infections
Chloroquine is a weak base, commonly used in the treatment
of malaria and autoimmune diseases such as rheumatoid
arthritis and systemic lupus erythematosus.15–23 It is readily
absorbed when administered by either oral or parenteral
routes,15–23 becoming highly concentrated in tissues such as
the adrenal glands, liver, spleen and kidney15–18,23 – tissues
suffering extensive necrosis in fatal ﬁloviral infections.1,2,4
In the cells of these and other tissues, CQ becomes concentrated
in acidic organelles such as the endosomes, lysosomes and
Golgi vesicles,16–18,24–30 thereby increasing their pH24–29,31
and leading to the dysfunction of several enzymes, e.g. those re-
quired for the proteolytic processing and the post-translational
modiﬁcation of proteins.10,24,25,27,31–34 CQ also inhibits the
production of several immunological mediators, the excessive
release of which contributes to autoimmune diseases such as
systemic lupus erythematosus and rheumatoid arthritis.18,24
Therefore, these CQ properties should be considered in
the treatment for ﬁloviral infections and their associated
pathologies.
The CQ-increased pH of the acidic organelles has been
shown to inhibit several viruses – including inﬂuenza A
and B, SARS coronavirus, hepatitis A virus and the Borna
disease virus –which all require a low pH for entry.24,34–40 This
suggests that CQ could also inhibit ﬁloviruses’ entry into the
cytoplasm of susceptible cells and thereby abrogate their infec-
tion, since this is dependent on endosomal acidiﬁcation and the
activities of several host endosomal proteases. CQ might also
inhibit the assembly and budding of ﬁloviruses – which partly
require the late endosome in their assembly.1,2
Accordingly, the dysfunction of enzymes, e.g. some
glycosyltransferases, caused by CQ or hydroxychloroquine
(HCQ), as a direct result of the increased pH and/or structural
changes in the Golgi apparatus, has been shown to inhibit not
only the glycosylation of SARS coronavirus,34 but also that of
HIV-1 gp120, thereby leading to the production of noninfec-
tious virions or virus with decreased infectivity.31,33,40,41 This
mechanism has been invoked to explain the decrease in viral
load that was observed when patients with HIV-1 were orally
administered HCQ at 800mg/day for 8weeks.31,42 These re-
sults, though obtained with nonrelated viruses, could suggest
that CQ, if given at the correct dosage, might inhibit the glyco-
sylation of EboV peplomers, which is more pronounced than
that occurring with HIV-1.1–3,43 Since the GP of ﬁloviruses
is the only protein involved in initiating infection,1,2,5,6,8 and
cytotoxicity is dependent on its expression,1,2,5 inhibiting its
glycosylation could potentially (1) inhibit EboV tropism for
a broad variety of host cells and organs; (2) lead to the produc-
tion of noninfectious or decreased infectivity virus (as seen
with HIV-1)31,33; and (3) decrease Ebov pathogenicity. Im-
paired glycosylation could therefore save time for the adaptive
immune response, which normally fails in fatal cases,1,2,11 to
be established and deal with the infection.
Therapeutically exploiting the immunomodulatory
properties of chloroquine in the treatment of ﬁloviral
infections
Apart from therapeutically exploiting the increased pH and
dysfunction of enzymes caused by CQ, the immunomodulatory
properties of this drug could also be exploited therapeutically in
the treatment of some of ﬁloviral infection-associated pa-
thologies. Several studies have suggested that the multiple
organ failure and hypovolemic shock seen in fatal cases are
likely a result of both direct infection and destruction of
susceptible cells, such as endothelial cells, and the effect
of pro-inﬂammatory cytokines, chemokines and other me-
diators released from infected and activated cells, such as
monocytes and macrophages.1,2,4,6,10–12,44
One cytokine strongly implicated in these pathologies is
TNF-α,1,2,7,12,13 which is able to increase the permeability
of endothelial cells, as shown in experiments conducted
with the human umbilical vein.1,2,7 It is also able – in
humans injected with a recombinant form – to induce a
sustained activation of blood coagulation and also cause tis-
sue injury and shock.45–47 The role of TNF-α in the pathologies
and fatalities associated with ﬁloviral infections is further
conﬁrmed by the fact that (1) intramuscular administration
of anti-TNF-α serum, after 4–7 days postinfection, is able
to reduce the circulating concentration of TNF-α and pro-
tect 50% of infected rodents from death1,2; (2) patients
who recovered from infection with Zaire EboV (ZEboV)
in two recent outbreaks in Gabon had a transient increase
in the plasma concentration of TNF-α at the onset of infec-
tion – which then decreased during the course of the infec-
tion. Conversely, fatal cases display an increased and
sustained concentration of TNF-α.12 In these fatalities,
highly increased concentrations of soluble tumour necrosis
factor receptors were also detected.12 Taken together, these
observations clearly show that a therapeutic agent like CQ,
which is able to prevent the activation of macrophages and
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also inhibit the secretion of TNF-α from various cells at
clinically relevant concentrations,24,48–52 could be of some
beneﬁt in the treatment of ﬁloviral infections.
Another cytokine likely to be implicated in Ebola pathogen-
esis – especially the massive apoptosis or lymphopenia associ-
ated with fatal cases of EboV infections – is IFN-γ.11–13 It has
been reported that IFN-γ is able to increase cellular sensitivity
to apoptosis by upregulating the expression of Fas and Fas li-
gand,53 and in all fatal cases of EboV infection, the expression
of IFN-γ, Fas and Fas ligand was shown to be upregulated.11
Another mechanism by which IFN-γ might – at least in part –
account for the massive apoptosis detected in Filovirus infec-
tions is induction of production by monocytes/macrophages
of neopterin and its derivative, 7-8-dihydroneopterin.12,54 It
has been reported that neopterin and 7-8-dihydroneopterin
induce apoptosis in a rat alveolar cell line,54 and that the plasma
concentration of neopterin signiﬁcantly and progressively
increases throughout the disease course of all fatal cases of
ZEboV infections – but not in survivors.12 Therefore, the pro-
duction of neopterin and 7-8-dihydroneopterin upon IFN-γ
stimulation might also contribute to the massive apoptosis seen
in fatal cases of EboV infections.11–13
Thus, since the massive apoptosis seen in all fatal cases of
EboV-infected patients is associated with the production of
IFN-γ, neopterin and 7-8-dihydroneopterin, and TNF-α,11–13
a therapeutic agent like CQ, having been shown, at clinically
relevant concentrations, to inhibit the production of IFN-γ,
TNF-α and neopterin from various cells,24,48–52 could be of
great beneﬁt in the treatment of patients infected with the pres-
ent ZEboV or other ﬁloviruses.
Sufﬁcient steady state chloroquine concentrations may be
needed to achieve its therapeutic effects
Although the above mechanisms of the action of CQ and the
various in vitro studies suggest that CQ may exert some ben-
eﬁt in infections from viruses that require an acidic pH for
infectivity and/or are heavily glycosylated and evoke a det-
rimental immune activation, several clinical trials that
attempted to use CQ or HCQ in the prevention or treatment
of several viral infections – including inﬂuenza A and B,
HIV-1 and dengue viral infections – have reported that CQ
or HCQ either had undetectable/moderate clinical efﬁcacy
or were actually detrimental (Table 1).42,55–66
It is possible to hypothesize that these mixed or disap-
pointing results may be attributable to not knowing – and
thus not achieving – the therapeutic steady state plasma or
whole blood CQ concentration necessary for exerting its
therapeutic effects (refer to the succeeding texts). In order
for CQ to be used for the treatment of infections from vi-
ruses that require an acidic pH for infectivity and/or are
heavily glycosylated and depend on their envelop glycopro-
tein for infectivity, the therapeutic steady state plasma or
whole blood concentration must be achieved and sustained
until the patient’s viraemia becomes undetectable. In the
succeeding texts, I summarize some of the evidence that
can be used to determine the necessary therapeutic, steady
state plasma or whole blood CQ concentration.
Firstly, several in vitro studies have shown that the optimal
uptake of CQ in several cell types isolated from different ani-
mals is in the range of 10–20μM, with concentrations
>~30μM, causing less uptake.26,30
Secondly, the whole blood CQ EC50 of 17.7μM/L is con-
sidered to be an in vivo threshold of CQ toxicity since it is a
Table 1. Outcome of several clinical trials, anecdotal trials and an animal study on the efﬁcacy of CQ or HCQ in the treatment of low pH-dependent or
pH-independent viral infections
Type of 4-AQ,
route Dose and duration
Infection/Type
of study
Plasma drug concentration
(ng/mL)
Outcome of
trial n Reference
HCQ, po 800mg/d; 8 weeks HIV-1/CT Steady state of 27 to
1000.4; mean of 316.3
Moderate efﬁcacy; patient with highest
concentration showed the best response.
40 42
CQ, po 250–500mg/d;
8 weeks
HIV-1/CT Not stated Signiﬁcant reduction of immune activation,
but no effect on viral load
12 58
CQ, po 200mg/d; 16 weeks HIV-1/CT Not stated No efﬁcacy 20 59
HCQ, po 400mg/d; 48 weeks HIV/CT Not stated Increased viral load in nine of the patients 42 60
HCQ, po 400mg/d; 6 months HIV-1/CT Not stated Signiﬁcant reduction of immune activation 20 61
CQ, po 500mg/d for 1 week,
then once a week
until the 12th week
Inﬂuenza-A/CT Not stated No efﬁcacy 724 55
CQ, po Day 1 = 600mg
Day 2 = 300mg
Day 3 = 300mg
Dengue/CT Not stated No efﬁcacy 153 56
CQ, po 500mg/d; 3 days Dengue/CT Not stated Improved dengue-related symptoms, which
returned after medication was stopped
19 57
CQ, parenteral Not stated Ebola/Anecdotal Not measured Patient fever resolved rapidly and remained
afebrile for 6 days, but died latter from
symptoms indicative of Ebola infection
1 62
CQ Not stated Ebola/Anecdotal Not measured No efﬁcacy stated 1 63
CQ, ip 90mg/kg; twice
daily for14 days
Ebola/Animal
study
Steady state whole blood
concentration of 2.5 μg/mL
85% survival rate 20 64
po, oral administration; ip, intraperitoneal; CT, clinical trial; d, day; AQ, aminoquinoline; CQ, chloroquine; HCQ, hydroxychloroquine.
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level associated with signiﬁcant cardiovascular effects in
patients with CQ poisoning,67 whilst patients having con-
centrations of 16μM/L were shown to have no signiﬁcant
cardiovascular events.67
Thirdly, out of all the clinical trials summarized in
Table 1, only the trial that administered the highest
HCQ dose, for a duration sufﬁcient to attain a steady
state (0.08 to 2.98μM/L, mean = 0.94μM/L), reported a
moderate improvement in several of the patients.42 Of
all the patients, only the one with the highest HCQ level
(2.98μM/L) (which is approximately equivalent to the
in vitro CQ EC50 of ~3μM shown to inhibit HIV-1
replication33) had the best response to HCQ. This
patient’s absolute CD4+ T-cells increased from 200 to
400 cells/mm3, the plasma levels of HIV-1 RNA
decreased from 225 to 135 cpm, the percentage of
CD4+ T-cells increased from 11% to 34%, and there
was also a signiﬁcant improvement in mitogen responses.42
Although HIV does not depend on the acidic organelles
for infectivity and is less glycosylated in comparison to
EboV,1–3,43 HCQ, at this steady state concentration, is nev-
ertheless able to inhibit HIV replication by affecting gp120
glycosylation.31,33,42
Fourthly, the steady state CQ/HCQ concentrations of
1μg/mL (~3.125μM/L) and ~16μM/L detected in plasma
and whole blood respectively, have been shown both in vivo
and in vitro to inhibit viral replication and the overproduction
of some immunological mediators associated with the pa-
thologies of many viral infections and some autoimmune
diseases.22,48,64,68–70
I conclude that (1) a 16μM/L transient or steady state
whole blood concentration of CQ most likely has no signiﬁ-
cant cardiovascular events22,42,67–69; (2) ~16μM/L steady
state whole blood concentration of CQ/HCQ is able to inhibit
viral replication, glycosylation and the over production of
some immunological mediators associated with some viral
infections22,33–35,38,39,42,64,67–70; (3) the optimal uptake of
CQ in humans is likely to lie within the range of 10–
20μM/L. Therefore, such a steady state CQ concentration
could be safe and sufﬁcient to raise and maintain the acidic
organelles’ pH to a level approximately neutral, thereby
inhibiting viral replication by mechanisms such as inhibi-
tion of endosomal proteases, inhibition of the fusion of vi-
ral membrane with host cells plasma membranes and
inhibition of viral glycosylation.
In order to achieve the recommended therapeutic steady
state plasma or whole blood CQ concentrations, the use of
slow, continuous and constant IV infusion could be recom-
mendable, since (1) it could be more efﬁcient in achieving
the stated therapeutic concentration and (2) it is more con-
trolled, given the low cardiovascular safety margin of
CQ.18,21
Having recommended the use of constant IV infusion,
suggesting a precise dose and an infusion rate for ﬁloviral
infection treatment (as in the treatment of malaria), though
seemingly reasonably, is, however, impossible at this stage.
This is primarily because of the interindividual differences
in the pharmacokinetics of CQ absorption.69,71
CONCLUSION
I conclude that 1μg/mL (~3.125μM/L) or 16μM/L steady
state CQ concentration in plasma or whole blood respec-
tively, could be used for the treatment of ﬁloviral and other
infections by viruses requiring an acidic pH for infectivity,
and that these concentrations need to be sustained until the
patients’ viraemia becomes undetectable. These stated con-
centrations, however, do not rule out the efﬁcacy of other,
higher, steady state concentrations – though such concentra-
tions might be accompanied by severe adverse effects or
toxicities. Other subsequent research has supported the con-
clusion in the preceding texts by conﬁrming that a derivative
of CQ has some protective effect against Ebola infection in
humans.72
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